Breaking News, Promotions & Moves

Genezen Names Steven Favaloro CEO

Favaloro brings extensive experience in gene and cell therapy, on both the innovator and CDMO side.

Genezen, a gene and cell therapy contract development and manufacturing organization (CDMO) specializing in lentiviral and retroviral vector manufacturing, appointed  Steven Favaloro President and CEO. Favaloro brings extensive experience in gene and cell therapy, on both the innovator and CDMO side, from executive positions at Arbor Biotechnologies, Arranta Bio, and Brammer Bio. Bill Vincent, founder and executive chairman of Genezen, said, “Steve’s track record in the C...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters